<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994890</url>
  </required_header>
  <id_info>
    <org_study_id>A4091043</org_study_id>
    <secondary_id>SC OA SAFETY STUDY</secondary_id>
    <nct_id>NCT00994890</nct_id>
  </id_info>
  <brief_title>A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections</brief_title>
  <official_title>A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND,LONG TERM STUDY OF THE SAFETY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety of three fixed dose levels of tanezumab (2.5 mg, 5 mg,&#xD;
      and 10 mg) administered at an 8-week interval by subcutaneous injection multiple (7) times&#xD;
      during the study treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety study of tanezumab in relief of osteoarthritis pain This study was terminated on 6&#xD;
      December 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies&#xD;
      which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.&#xD;
  </why_stopped>
  <start_date type="Actual">November 17, 2009</start_date>
  <completion_date type="Actual">March 1, 2011</completion_date>
  <primary_completion_date type="Actual">December 7, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 112 days after last dose of study medication (up to 345 days)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline to Week 50</time_frame>
    <description>Laboratory analysis included blood chemistry, hematology, urinalysis and pregnancy test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Week 50</time_frame>
    <description>All standard intervals (PR, QRS, QT, QT interval corrected for heart rate using Fridericia's formula [QTcF], QT interval corrected for heart rate using Bazett's formula [QTcB], RR intervals and heart rate) were analyzed. Participants with abnormal ECG findings reported as adverse events were presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 2</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 4</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 32</measure>
    <time_frame>Baseline, Week 32</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 40</measure>
    <time_frame>Baseline, Week 40</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Physical Findings</measure>
    <time_frame>Baseline to Week 50</time_frame>
    <description>Physical examination included examination of abdomen, ears, extremities, eyes, head, heart, lungs, lymph nodes, neck, nose, skin, throat, thyroid, muscoskeletal, neurological and peripheral vascular system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) at Week 50</measure>
    <time_frame>Week 50</time_frame>
    <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Sign Abnormalities</measure>
    <time_frame>Baseline up to Week 50</time_frame>
    <description>Examination of vital signs included body temperature, systolic blood pressure, diastolic blood pressure, pulse rate and respiratory rate. Participants with abnormal vital sign findings reported as adverse events were presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection-Site Reactions at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 to 10, where higher scores indicated higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint and index hip during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on NRS of 0 to 10, with higher scores indicated worse function. Total score range for WOMAC physical function subscale score was 0 to 10, where higher scores indicated worse function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8,16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>OMERACT-OARSI response: greater than or equal to (&gt;=) 50 percent (%) improvement from baseline and absolute change from baseline of &gt;=2 units in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: &gt;=20% improvement from baseline and absolute change from baseline of &gt;=1 unit in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>Percentage of participants with at least 30%, 50%, 70% and 90% reduction from baseline in WOMAC pain subscale score are reported. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a 0 to 10 NRS, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicated higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement of At Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good and 5 = very poor. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of 0 to 10, with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee or hip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee or hip. Each item was scored on a 0 to 10 NRS scale, where higher scores indicated higher pain/stiffness or worse function. WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranged from 0 to 10, where higher score indicated worse response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>Participants answered: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
    <description>Participants answered: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation Due to Lack of Efficacy</measure>
    <time_frame>Baseline up to Week 50</time_frame>
    <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to Lack of Efficacy</measure>
    <time_frame>Baseline up to Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Used Concomitant Analgesic Medication</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56, 64</time_frame>
    <description>United States Food and Drug Administration (FDA) approved analgesics were permitted as concomitant medications to relieve the pain of osteoarthritis. These medications included opioids, topical analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Per Week of Concomitant Analgesic Medication Usage</measure>
    <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56, 64</time_frame>
    <description>United States FDA-approved analgesics were permitted as concomitant medications to relieve the pain of OA. These medications included opioids, topical analgesics, NSAIDs, capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Subcutaneous Doses of Study Medication</measure>
    <time_frame>Day 1 up to Week 24</time_frame>
    <description>Number of participants are reported based on the maximum number of subcutaneous doses of study medication received.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">679</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanezumab 2.5 mg</intervention_name>
    <description>Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 2.5 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanezumab 5 mg</intervention_name>
    <description>Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 5 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tanezumab 10 mg</intervention_name>
    <description>Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year</description>
    <arm_group_label>Tanezumab 10 mg</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis of the knee or hip based on American College of Rheumatology criteria&#xD;
             with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of â‰¥2);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) of &gt;39 kg/m2;&#xD;
&#xD;
          -  Pregnancy or intent to become pregnant&#xD;
&#xD;
          -  Planned surgical procedure during the duration of the study&#xD;
&#xD;
          -  History of clinically significant cardiovascular, central nervous system or&#xD;
             psychiatric disease&#xD;
&#xD;
          -  Previous exposure to exogenous NGF or to an anti NGF antibody;&#xD;
&#xD;
          -  Use of biologics other than study medication, Live or live-attenuated intranasal&#xD;
             vaccines (eg, Flumist), are allowable exceptions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mobile Diagnostic Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Management, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Rheumatology Specialists, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Arthritis Care and Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalina Pointe Clinical Research, Inc</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ft. Smith Rheumatology, PC</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry Watkins, MD</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OrthoArkansas, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiology Consultants</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Care Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staywell Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Imaging Centers</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C Michael Neuwelt, MD</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Center Medical Group</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research</name>
      <address>
        <city>Lauderdale Lake</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Internal Medicine Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIMA Century Research Associate</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osler Medical, Inc.</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>344471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Family Medical</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paddock Park Clinical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pensacola Research Consultants, Inc.</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarred Frydman, DO</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Center of South Flordia</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Arthritis and Rheumatic Diseases</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North Georgia</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Group Rheumatology</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Research Administration Office</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Health Physicians</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61103-3692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graves Gilbert Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Medical Research Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sterling Clinic</name>
      <address>
        <city>Mount Sterling</city>
        <state>Kentucky</state>
        <zip>40353</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Clinical Trails, Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodrail Clinic</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Physicians</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Internal Medicine</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clayton Medical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Clinical Research Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Center for Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara A. Caciolo</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research, Inc</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medical Associates of Grand Island, PC</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Rheumatology</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research Associates</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Consultants of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert A. Harrell, MD</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Imaging</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source, Inc.</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43551</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Joint &amp; Spine Surgeons, Inc.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBride Clinic</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Research Consultants</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Medical Group PC/Fleetwood Clinical Research</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <zip>19522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America @ Oyster Point Family Health Center</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny North Arthritis Center</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffry A. Lindenbaum D.O., P.C.</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anderson Radiology</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Care Associates</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Health Specialists</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute, LLC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolf River Medical Group. LLC</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jackson Clinic, PA</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of John M. Joseph, M.D.</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care and Diagnostic Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Medical Research Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nothwest Diagonstic Clinic, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Center of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Research Center, LP</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic, Office of Research Administration</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic, Rheumatology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians' Research Options, LLC</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lone Peak Family Medicine</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Granger Medical Clinic</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Associates, PC</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan E. Schulman, MD</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Maestrello, M.D.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Neiman, MD Inc.</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Puget Sound Clinical Research Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology and Pulmonary Clinic</name>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <zip>25801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Advanced Healthcare</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091043&amp;StudyName=A%20Long%20Term%20Study%20of%20the%20Safety%20of%20Tanezumab%20When%20Administered%20By%20Subcutaneous%20Injections</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 12, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <results_first_submitted>February 25, 2021</results_first_submitted>
  <results_first_submitted_qc>April 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2021</results_first_posted>
  <disposition_first_submitted>October 1, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 1, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 5, 2012</disposition_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-blind safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tanezumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Due to United States Food and Drug Administration (FDA) imposed clinical hold, study was terminated prematurely and a maximum of only 4 doses of the 7 planned doses of tanezumab (RN624 or PF-04383119) subcutaneous injection were administered in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tanezumab 2.5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="222"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="197"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Tanezumab 2.5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="222"/>
            <count group_id="B3" value="226"/>
            <count group_id="B4" value="678"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18 to 44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="365"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than or equal to (&gt;=) 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="470"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Baseline up to 112 days after last dose of study medication (up to 345 days)</time_frame>
        <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <description>Laboratory analysis included blood chemistry, hematology, urinalysis and pregnancy test.</description>
        <time_frame>Baseline to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <description>Laboratory analysis included blood chemistry, hematology, urinalysis and pregnancy test.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>All standard intervals (PR, QRS, QT, QT interval corrected for heart rate using Fridericia's formula [QTcF], QT interval corrected for heart rate using Bazett's formula [QTcB], RR intervals and heart rate) were analyzed. Participants with abnormal ECG findings reported as adverse events were presented.</description>
        <time_frame>Baseline up to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>All standard intervals (PR, QRS, QT, QT interval corrected for heart rate using Fridericia's formula [QTcF], QT interval corrected for heart rate using Bazett's formula [QTcB], RR intervals and heart rate) were analyzed. Participants with abnormal ECG findings reported as adverse events were presented.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atrioventricular block first degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bundle branch block right</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supraventricular tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG QRS complex prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG T wave abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG T wave inversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 2</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 2</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 2</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="229"/>
                    <count group_id="O2" value="222"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="3.93"/>
                    <measurement group_id="O2" value="1.52" spread="3.17"/>
                    <measurement group_id="O3" value="1.76" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="218"/>
                    <count group_id="O3" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="1.51"/>
                    <measurement group_id="O2" value="-0.36" spread="2.04"/>
                    <measurement group_id="O3" value="-0.23" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 4</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 4</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="1.72"/>
                    <measurement group_id="O2" value="-0.15" spread="2.12"/>
                    <measurement group_id="O3" value="-0.10" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 8</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 8</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="216"/>
                <count group_id="O3" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="2.10"/>
                    <measurement group_id="O2" value="-0.08" spread="2.30"/>
                    <measurement group_id="O3" value="-0.34" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 16</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 16</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="2.24"/>
                    <measurement group_id="O2" value="-0.17" spread="2.66"/>
                    <measurement group_id="O3" value="-0.24" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 24</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 24</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="2.14"/>
                    <measurement group_id="O2" value="-0.38" spread="2.53"/>
                    <measurement group_id="O3" value="-0.19" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 32</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 32</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 32</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="2.15"/>
                    <measurement group_id="O2" value="-0.11" spread="2.26"/>
                    <measurement group_id="O3" value="-0.34" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 40</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 40</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 40</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="2.11"/>
                    <measurement group_id="O2" value="-0.39" spread="1.41"/>
                    <measurement group_id="O3" value="0.00" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 48</title>
        <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Results are not reported for Tanezumab 5 mg group because all participants in this group had discontinued the study before Week 48.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropathy Impairment Score (NIS) at Week 48</title>
          <description>NIS: 74-item, assess cranial nerves, muscle weakness, reflexes, sensation; scored separately for left, right limbs (37 items for each). Cranial nerves included 5 items (3rd nerve, 6th nerve, facial weakness, palate weakness, tongue weakness), muscle weakness included 19 items (respiratory,neck flexion, shoulder abduction, elbow flexion, brachioradialis,elbow extension, wrist flexion,wrist extension,finger flexion,finger spread,thumb abduction,hip flexion,hip extension,knee flexion,knee extension,ankle dorsiflexors,ankle plantar flexors,toe extensors,toe flexors), each item scored on scale 0=normal to 4=paralysis, higher score=greater weakness. Reflexes included 5 items (quadriceps femoris, triceps surae, biceps brachii, triceps brachii, brachioradialis), sensation included 4 items each for great toe and index finger (touch pressure, pin prick, vibration, joint position), each item scored as 0=normal, 1=decreased, 2=absent. Total NIS score range 0-244, higher score=greater impairment.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Results are not reported for Tanezumab 5 mg group because all participants in this group had discontinued the study before Week 48.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="NA">Standard deviation was not estimable since only 1 participant was evaluable in this group.</measurement>
                    <measurement group_id="O3" value="0.00" spread="NA">Standard deviation was not estimable since only 1 participant was evaluable in this group.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Change From Baseline in Physical Findings</title>
        <description>Physical examination included examination of abdomen, ears, extremities, eyes, head, heart, lungs, lymph nodes, neck, nose, skin, throat, thyroid, muscoskeletal, neurological and peripheral vascular system.</description>
        <time_frame>Baseline to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change From Baseline in Physical Findings</title>
          <description>Physical examination included examination of abdomen, ears, extremities, eyes, head, heart, lungs, lymph nodes, neck, nose, skin, throat, thyroid, muscoskeletal, neurological and peripheral vascular system.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) at Day 1</title>
        <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Day 1</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) at Day 1</title>
          <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative enzyme-linked immunosorbent assay (ELISA).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 8</title>
        <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 8</title>
          <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 24</title>
        <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
        <time_frame>Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 24</title>
          <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 50</title>
        <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
        <time_frame>Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-Drug Antibody (ADA) at Week 50</title>
          <description>Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using the semi-quantitative ELISA.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure at any time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Sign Abnormalities</title>
        <description>Examination of vital signs included body temperature, systolic blood pressure, diastolic blood pressure, pulse rate and respiratory rate. Participants with abnormal vital sign findings reported as adverse events were presented.</description>
        <time_frame>Baseline up to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Abnormalities</title>
          <description>Examination of vital signs included body temperature, systolic blood pressure, diastolic blood pressure, pulse rate and respiratory rate. Participants with abnormal vital sign findings reported as adverse events were presented.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood pressure increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Day 1</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Day 1</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Day 1</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 2</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 2</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 2</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="221"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 4</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 4</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 4</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 8</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 8</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 8</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 16</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 16</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 16</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="123"/>
                <count group_id="O3" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 24</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 24</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 32</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 32</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 32</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection-Site Reactions at Week 40</title>
        <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
        <time_frame>Week 40</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection-Site Reactions at Week 40</title>
          <description>Assessment of the injection-site reactions were based on presence of erythema (redness), induration (swelling), ecchymosis (bruising), pruritus (itching) and pain that occurred after the injection had been administered (not related to pain of needle insertion).</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 to 10, where higher scores indicated higher pain.</description>
        <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 to 10, where higher scores indicated higher pain.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.35" spread="1.48"/>
                    <measurement group_id="O2" value="6.48" spread="1.56"/>
                    <measurement group_id="O3" value="6.30" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="2.02"/>
                    <measurement group_id="O2" value="-1.97" spread="2.18"/>
                    <measurement group_id="O3" value="-1.61" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="2.11"/>
                    <measurement group_id="O2" value="-2.68" spread="2.15"/>
                    <measurement group_id="O3" value="-2.50" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="2.14"/>
                    <measurement group_id="O2" value="-2.76" spread="2.25"/>
                    <measurement group_id="O3" value="-2.71" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="2.25"/>
                    <measurement group_id="O2" value="-2.85" spread="2.32"/>
                    <measurement group_id="O3" value="-2.71" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.16" spread="2.29"/>
                    <measurement group_id="O2" value="-2.84" spread="2.31"/>
                    <measurement group_id="O3" value="-2.69" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="2.26"/>
                    <measurement group_id="O2" value="-2.82" spread="2.32"/>
                    <measurement group_id="O3" value="-2.66" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint and index hip during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on NRS of 0 to 10, with higher scores indicated worse function. Total score range for WOMAC physical function subscale score was 0 to 10, where higher scores indicated worse function.</description>
        <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint and index hip during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on NRS of 0 to 10, with higher scores indicated worse function. Total score range for WOMAC physical function subscale score was 0 to 10, where higher scores indicated worse function.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="1.54"/>
                    <measurement group_id="O2" value="6.58" spread="1.55"/>
                    <measurement group_id="O3" value="6.47" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10" spread="2.01"/>
                    <measurement group_id="O2" value="-2.13" spread="2.15"/>
                    <measurement group_id="O3" value="-1.92" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="2.16"/>
                    <measurement group_id="O2" value="-2.70" spread="2.22"/>
                    <measurement group_id="O3" value="-2.64" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="2.10"/>
                    <measurement group_id="O2" value="-2.83" spread="2.26"/>
                    <measurement group_id="O3" value="-2.80" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="2.20"/>
                    <measurement group_id="O2" value="-2.89" spread="2.35"/>
                    <measurement group_id="O3" value="-2.84" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="2.23"/>
                    <measurement group_id="O2" value="-2.89" spread="2.37"/>
                    <measurement group_id="O3" value="-2.84" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="2.22"/>
                    <measurement group_id="O2" value="-2.90" spread="2.36"/>
                    <measurement group_id="O3" value="-2.79" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8,16, 24, 32, 40, 48 and 56</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities).</description>
        <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8,16, 24, 32, 40, 48 and 56</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good (no symptom and limitation of normal activities) and 5 = very poor (very severe symptoms and inability to carry out normal activities).</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.59"/>
                    <measurement group_id="O2" value="3.36" spread="0.57"/>
                    <measurement group_id="O3" value="3.32" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.78"/>
                    <measurement group_id="O2" value="-0.64" spread="0.85"/>
                    <measurement group_id="O3" value="-0.64" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="0.79"/>
                    <measurement group_id="O2" value="-0.86" spread="0.86"/>
                    <measurement group_id="O3" value="-0.77" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.80"/>
                    <measurement group_id="O2" value="-0.83" spread="0.83"/>
                    <measurement group_id="O3" value="-0.82" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.83"/>
                    <measurement group_id="O2" value="-0.84" spread="0.86"/>
                    <measurement group_id="O3" value="-0.80" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.87"/>
                    <measurement group_id="O2" value="-0.82" spread="0.88"/>
                    <measurement group_id="O3" value="-0.80" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.88"/>
                    <measurement group_id="O2" value="-0.82" spread="0.88"/>
                    <measurement group_id="O3" value="-0.80" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response</title>
        <description>OMERACT-OARSI response: greater than or equal to (&gt;=) 50 percent (%) improvement from baseline and absolute change from baseline of &gt;=2 units in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: &gt;=20% improvement from baseline and absolute change from baseline of &gt;=1 unit in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response</title>
          <description>OMERACT-OARSI response: greater than or equal to (&gt;=) 50 percent (%) improvement from baseline and absolute change from baseline of &gt;=2 units in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: &gt;=20% improvement from baseline and absolute change from baseline of &gt;=1 unit in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" lower_limit="51" upper_limit="64"/>
                    <measurement group_id="O2" value="58.6" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="O3" value="49.3" lower_limit="43" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" lower_limit="59" upper_limit="71"/>
                    <measurement group_id="O2" value="70.5" lower_limit="64" upper_limit="76"/>
                    <measurement group_id="O3" value="73.5" lower_limit="68" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="55" upper_limit="68"/>
                    <measurement group_id="O2" value="68.6" lower_limit="63" upper_limit="75"/>
                    <measurement group_id="O3" value="70.9" lower_limit="65" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="53" upper_limit="66"/>
                    <measurement group_id="O2" value="68.6" lower_limit="63" upper_limit="75"/>
                    <measurement group_id="O3" value="72.2" lower_limit="66" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="O2" value="68.2" lower_limit="62" upper_limit="74"/>
                    <measurement group_id="O3" value="71.7" lower_limit="66" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2" lower_limit="52" upper_limit="65"/>
                    <measurement group_id="O2" value="68.2" lower_limit="62" upper_limit="74"/>
                    <measurement group_id="O3" value="71.7" lower_limit="66" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
        <description>Percentage of participants with at least 30%, 50%, 70% and 90% reduction from baseline in WOMAC pain subscale score are reported. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a 0 to 10 NRS, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicated higher pain.</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
          <description>Percentage of participants with at least 30%, 50%, 70% and 90% reduction from baseline in WOMAC pain subscale score are reported. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It was calculated as mean of the scores from the 5 individual questions scored on a 0 to 10 NRS, where higher scores indicated higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicated higher pain.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" lower_limit="42" upper_limit="55"/>
                    <measurement group_id="O2" value="49.1" lower_limit="42" upper_limit="56"/>
                    <measurement group_id="O3" value="41.4" lower_limit="35" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" lower_limit="23" upper_limit="34"/>
                    <measurement group_id="O2" value="31.4" lower_limit="25" upper_limit="37"/>
                    <measurement group_id="O3" value="23.9" lower_limit="18" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="9" upper_limit="18"/>
                    <measurement group_id="O2" value="16.8" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O3" value="14.0" lower_limit="9" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="51" upper_limit="64"/>
                    <measurement group_id="O2" value="62.7" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O3" value="60.4" lower_limit="54" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" lower_limit="33" upper_limit="45"/>
                    <measurement group_id="O2" value="40.9" lower_limit="34" upper_limit="47"/>
                    <measurement group_id="O3" value="41.0" lower_limit="35" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="16" upper_limit="27"/>
                    <measurement group_id="O2" value="24.5" lower_limit="19" upper_limit="30"/>
                    <measurement group_id="O3" value="22.5" lower_limit="17" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="6.8" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O3" value="6.3" lower_limit="3" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="44" upper_limit="57"/>
                    <measurement group_id="O2" value="62.7" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O3" value="66.2" lower_limit="60" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="29" upper_limit="41"/>
                    <measurement group_id="O2" value="46.4" lower_limit="40" upper_limit="53"/>
                    <measurement group_id="O3" value="46.4" lower_limit="40" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O2" value="26.8" lower_limit="21" upper_limit="33"/>
                    <measurement group_id="O3" value="27.0" lower_limit="21" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="O3" value="10.8" lower_limit="7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="46" upper_limit="59"/>
                    <measurement group_id="O2" value="62.3" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O3" value="65.3" lower_limit="59" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="31" upper_limit="44"/>
                    <measurement group_id="O2" value="50.0" lower_limit="43" upper_limit="57"/>
                    <measurement group_id="O3" value="45.5" lower_limit="39" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O2" value="28.6" lower_limit="23" upper_limit="35"/>
                    <measurement group_id="O3" value="28.4" lower_limit="22" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" lower_limit="3" upper_limit="9"/>
                    <measurement group_id="O2" value="11.8" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="O3" value="12.2" lower_limit="8" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" lower_limit="44" upper_limit="57"/>
                    <measurement group_id="O2" value="62.7" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O3" value="65.3" lower_limit="59" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="31" upper_limit="44"/>
                    <measurement group_id="O2" value="50.0" lower_limit="43" upper_limit="57"/>
                    <measurement group_id="O3" value="45.5" lower_limit="39" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O2" value="28.2" lower_limit="22" upper_limit="34"/>
                    <measurement group_id="O3" value="28.8" lower_limit="23" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O2" value="11.8" lower_limit="8" upper_limit="16"/>
                    <measurement group_id="O3" value="11.7" lower_limit="7" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: at least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" lower_limit="45" upper_limit="58"/>
                    <measurement group_id="O2" value="62.3" lower_limit="56" upper_limit="69"/>
                    <measurement group_id="O3" value="64.9" lower_limit="59" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: at least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" lower_limit="31" upper_limit="43"/>
                    <measurement group_id="O2" value="49.5" lower_limit="43" upper_limit="56"/>
                    <measurement group_id="O3" value="44.1" lower_limit="38" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: at least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O2" value="27.7" lower_limit="22" upper_limit="34"/>
                    <measurement group_id="O3" value="27.9" lower_limit="22" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: at least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7" upper_limit="16"/>
                    <measurement group_id="O3" value="11.3" lower_limit="7" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
        <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score</title>
          <description>WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 to 10, where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline at Week 16 are reported.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16: greater than (&gt;) 0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6"/>
                    <measurement group_id="O2" value="85.2"/>
                    <measurement group_id="O3" value="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8"/>
                    <measurement group_id="O2" value="81.5"/>
                    <measurement group_id="O3" value="82.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=20%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2"/>
                    <measurement group_id="O2" value="71.9"/>
                    <measurement group_id="O3" value="73.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=30%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="63.0"/>
                    <measurement group_id="O3" value="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=40%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0"/>
                    <measurement group_id="O2" value="57.0"/>
                    <measurement group_id="O3" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=60%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0"/>
                    <measurement group_id="O2" value="41.5"/>
                    <measurement group_id="O3" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=70%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="32.6"/>
                    <measurement group_id="O3" value="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=80%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="21.5"/>
                    <measurement group_id="O3" value="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=90%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 100%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement of At Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good and 5 = very poor. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement of At Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your knee (or hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point scale where 1 = very good and 5 = very poor. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="10" upper_limit="19"/>
                    <measurement group_id="O2" value="15.8" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O3" value="13.3" lower_limit="9" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="15" upper_limit="25"/>
                    <measurement group_id="O2" value="20.3" lower_limit="15" upper_limit="26"/>
                    <measurement group_id="O3" value="16.9" lower_limit="12" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O2" value="18.9" lower_limit="14" upper_limit="24"/>
                    <measurement group_id="O3" value="24.9" lower_limit="19" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="11" upper_limit="20"/>
                    <measurement group_id="O2" value="18.0" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="O3" value="20.9" lower_limit="16" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="12" upper_limit="22"/>
                    <measurement group_id="O2" value="18.5" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O3" value="20.0" lower_limit="15" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O2" value="18.5" lower_limit="13" upper_limit="24"/>
                    <measurement group_id="O3" value="20.0" lower_limit="15" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of 0 to 10, with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee or hip.</description>
        <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or index hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of 0 to 10, with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is 0 to 10, where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee or hip.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" lower_limit="6.55" upper_limit="7.01"/>
                    <measurement group_id="O2" value="6.85" lower_limit="6.61" upper_limit="7.08"/>
                    <measurement group_id="O3" value="6.73" lower_limit="6.50" upper_limit="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" lower_limit="-2.63" upper_limit="-2.02"/>
                    <measurement group_id="O2" value="-2.42" lower_limit="-2.75" upper_limit="-2.10"/>
                    <measurement group_id="O3" value="-2.29" lower_limit="-2.61" upper_limit="-1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.73" lower_limit="-3.05" upper_limit="-2.40"/>
                    <measurement group_id="O2" value="-3.01" lower_limit="-3.34" upper_limit="-2.68"/>
                    <measurement group_id="O3" value="-2.99" lower_limit="-3.31" upper_limit="-2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" lower_limit="-2.75" upper_limit="-2.10"/>
                    <measurement group_id="O2" value="-3.17" lower_limit="-3.50" upper_limit="-2.84"/>
                    <measurement group_id="O3" value="-3.05" lower_limit="-3.41" upper_limit="-2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" lower_limit="-2.76" upper_limit="-2.10"/>
                    <measurement group_id="O2" value="-3.20" lower_limit="-3.54" upper_limit="-2.87"/>
                    <measurement group_id="O3" value="-3.15" lower_limit="-3.50" upper_limit="-2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" lower_limit="-2.75" upper_limit="-2.07"/>
                    <measurement group_id="O2" value="-3.20" lower_limit="-3.54" upper_limit="-2.86"/>
                    <measurement group_id="O3" value="-3.10" lower_limit="-3.45" upper_limit="-2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" lower_limit="-2.70" upper_limit="-2.03"/>
                    <measurement group_id="O2" value="-3.21" lower_limit="-3.55" upper_limit="-2.87"/>
                    <measurement group_id="O3" value="-3.05" lower_limit="-3.40" upper_limit="-2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee or hip. Each item was scored on a 0 to 10 NRS scale, where higher scores indicated higher pain/stiffness or worse function. WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranged from 0 to 10, where higher score indicated worse response.</description>
        <time_frame>Baseline, Week 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee or hip. Each item was scored on a 0 to 10 NRS scale, where higher scores indicated higher pain/stiffness or worse function. WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranged from 0 to 10, where higher score indicated worse response.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.54" spread="1.45"/>
                    <measurement group_id="O2" value="6.64" spread="1.50"/>
                    <measurement group_id="O3" value="6.50" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.99"/>
                    <measurement group_id="O2" value="-2.18" spread="2.13"/>
                    <measurement group_id="O3" value="-1.94" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="2.14"/>
                    <measurement group_id="O2" value="-2.80" spread="2.18"/>
                    <measurement group_id="O3" value="-2.71" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="2.11"/>
                    <measurement group_id="O2" value="-2.92" spread="2.24"/>
                    <measurement group_id="O3" value="-2.85" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="2.21"/>
                    <measurement group_id="O2" value="-2.98" spread="2.29"/>
                    <measurement group_id="O3" value="-2.90" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="2.26"/>
                    <measurement group_id="O2" value="-2.97" spread="2.32"/>
                    <measurement group_id="O3" value="-2.88" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="2.23"/>
                    <measurement group_id="O2" value="-2.98" spread="2.31"/>
                    <measurement group_id="O3" value="-2.83" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>Participants answered: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Subscale Item: Pain When Walking on a Flat Surface at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>Participants answered: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" spread="1.86"/>
                    <measurement group_id="O2" value="6.32" spread="1.84"/>
                    <measurement group_id="O3" value="6.20" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="2.17"/>
                    <measurement group_id="O2" value="-1.94" spread="2.38"/>
                    <measurement group_id="O3" value="-1.67" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="2.31"/>
                    <measurement group_id="O2" value="-2.59" spread="2.34"/>
                    <measurement group_id="O3" value="-2.45" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="2.42"/>
                    <measurement group_id="O2" value="-2.65" spread="2.50"/>
                    <measurement group_id="O3" value="-2.63" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="2.54"/>
                    <measurement group_id="O2" value="-2.66" spread="2.48"/>
                    <measurement group_id="O3" value="-2.57" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="2.55"/>
                    <measurement group_id="O2" value="-2.65" spread="2.51"/>
                    <measurement group_id="O3" value="-2.60" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.96" spread="2.51"/>
                    <measurement group_id="O2" value="-2.63" spread="2.51"/>
                    <measurement group_id="O3" value="-2.56" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
        <description>Participants answered: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 16, 24, 32, 40, 48, 56</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Subscale Item: Pain When Going Up or Down Stairs at Week 2, 4, 8, 16, 24, 32, 40, 48 and 56</title>
          <description>Participants answered: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. Missing data was imputed using last observation carried forward (LOCF) method. Due to implementation of the FDA clinical hold, all ongoing participants were discontinued from treatment and did not have an opportunity to complete the 56-week treatment period and no efficacy data beyond the Week 32 visit (i.e., Weeks 40, 48 and 56) was collected.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" spread="1.64"/>
                    <measurement group_id="O2" value="7.64" spread="1.68"/>
                    <measurement group_id="O3" value="7.54" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="2.28"/>
                    <measurement group_id="O2" value="-2.25" spread="2.43"/>
                    <measurement group_id="O3" value="-1.99" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.86" spread="2.58"/>
                    <measurement group_id="O2" value="-3.01" spread="2.47"/>
                    <measurement group_id="O3" value="-2.77" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.60" spread="2.48"/>
                    <measurement group_id="O2" value="-3.03" spread="2.59"/>
                    <measurement group_id="O3" value="-3.01" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="2.63"/>
                    <measurement group_id="O2" value="-3.05" spread="2.67"/>
                    <measurement group_id="O3" value="-3.01" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="2.66"/>
                    <measurement group_id="O2" value="-3.00" spread="2.67"/>
                    <measurement group_id="O3" value="-2.98" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="2.63"/>
                    <measurement group_id="O2" value="-3.01" spread="2.66"/>
                    <measurement group_id="O3" value="-2.94" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation Due to Lack of Efficacy</title>
        <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
        <time_frame>Baseline up to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation Due to Lack of Efficacy</title>
          <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and full range were not evaluable since no participant discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and full range were not evaluable since no participant discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="82.0" upper_limit="82.0">Median was not evaluable since only 1 participant discontinued due to lack of efficacy.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to Lack of Efficacy</title>
        <time_frame>Baseline up to Week 50</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Lack of Efficacy</title>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Used Concomitant Analgesic Medication</title>
        <description>United States Food and Drug Administration (FDA) approved analgesics were permitted as concomitant medications to relieve the pain of osteoarthritis. These medications included opioids, topical analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56, 64</time_frame>
        <population>ITT analysis set. 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group. Data were not collected beyond Week 48 due to premature termination of the study in response to FDA clinical hold.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Used Concomitant Analgesic Medication</title>
          <description>United States Food and Drug Administration (FDA) approved analgesics were permitted as concomitant medications to relieve the pain of osteoarthritis. These medications included opioids, topical analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
          <population>ITT analysis set. 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'Number Analyzed' signifies those participants who were evaluable for this measure at given time points for each group. Data were not collected beyond Week 48 due to premature termination of the study in response to FDA clinical hold.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="47" upper_limit="60"/>
                    <measurement group_id="O2" value="49.8" lower_limit="43" upper_limit="56"/>
                    <measurement group_id="O3" value="52.5" lower_limit="46" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" lower_limit="46" upper_limit="59"/>
                    <measurement group_id="O2" value="47.7" lower_limit="41" upper_limit="54"/>
                    <measurement group_id="O3" value="51.6" lower_limit="45" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="47" upper_limit="60"/>
                    <measurement group_id="O2" value="47.9" lower_limit="41" upper_limit="55"/>
                    <measurement group_id="O3" value="51.6" lower_limit="45" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" lower_limit="43" upper_limit="58"/>
                    <measurement group_id="O2" value="47.8" lower_limit="40" upper_limit="55"/>
                    <measurement group_id="O3" value="50.5" lower_limit="43" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="39" upper_limit="60"/>
                    <measurement group_id="O2" value="49.0" lower_limit="39" upper_limit="59"/>
                    <measurement group_id="O3" value="48.9" lower_limit="38" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="12" upper_limit="55"/>
                    <measurement group_id="O2" value="47.6" lower_limit="26" upper_limit="69"/>
                    <measurement group_id="O3" value="52.2" lower_limit="32" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Per Week of Concomitant Analgesic Medication Usage</title>
        <description>United States FDA-approved analgesics were permitted as concomitant medications to relieve the pain of OA. These medications included opioids, topical analgesics, NSAIDs, capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
        <time_frame>Week 2, 4, 8, 16, 24, 32, 40, 48, 56, 64</time_frame>
        <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'number analyzed' signifies those participants who were evaluable for this measure at given time points for each group. Data were not collected beyond Week 48 due to premature termination of the study in response to FDA clinical hold.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Per Week of Concomitant Analgesic Medication Usage</title>
          <description>United States FDA-approved analgesics were permitted as concomitant medications to relieve the pain of OA. These medications included opioids, topical analgesics, NSAIDs, capsaicin products and viscosupplementation (example, hyaluronan) and were prescribed at the discretion of the Investigator.</description>
          <population>ITT analysis set. Here, 'Overall number of participants analyzed' signifies those participants who were evaluable for this measure. 'number analyzed' signifies those participants who were evaluable for this measure at given time points for each group. Data were not collected beyond Week 48 due to premature termination of the study in response to FDA clinical hold.</population>
          <units>days per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="219"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                    <count group_id="O2" value="219"/>
                    <count group_id="O3" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="216"/>
                    <count group_id="O3" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="2.9" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="162"/>
                    <count group_id="O2" value="178"/>
                    <count group_id="O3" value="182"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Subcutaneous Doses of Study Medication</title>
        <description>Number of participants are reported based on the maximum number of subcutaneous doses of study medication received.</description>
        <time_frame>Day 1 up to Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Tanezumab 2.5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 5 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 10 mg</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subcutaneous Doses of Study Medication</title>
          <description>Number of participants are reported based on the maximum number of subcutaneous doses of study medication received.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of subcutaneous study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="222"/>
                <count group_id="O3" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Cases of osteonecrosis (ON) reported in this and other A409 studies conducted up to 2010 were adjudicated post-hoc by an expert committee(2010-2012). Few of these events (2 of 87 reported ON cases), were confirmed as ON by the committee. Source: https://doi.org/10.1002/art.39492</desc>
      <group_list>
        <group group_id="E1">
          <title>Tanezumab 2.5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 milligram (mg) injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tanezumab 5 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Tanezumab 10 mg</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg injection subcutaneously every 8 weeks up to 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Sphincter of Oddi dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acute generalised exanthematous pustulosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="226"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="226"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to United States FDA imposed clinical hold, enrollment was stopped and study was terminated prematurely. Due to this, injection-site reaction data were not collected beyond Week 40 and NIS data were not collected beyond Week 48.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

